Is PT-141 (Bremelanotide) Legal in Louisiana? How Women Can Access It Safely

The Short Answer: PT-141 Is Legal in Louisiana With a Prescription

PT-141, the peptide also sold under the brand name Vyleesi, is legal in Louisiana when prescribed by a licensed healthcare provider. No Louisiana state law bans bremelanotide. Federal law governs its status, and because the FDA approved it in 2019, it does not sit in the unregulated research-chemical space.

The distinction that matters for you as a patient is how you obtain it. Three legal pathways exist.

Pathway 1: Brand-Name Vyleesi From a Licensed Pharmacy

Palatin Technologies' FDA-approved Vyleesi (bremelanotide 1.75 mg/0.3 mL auto-injector) can be dispensed by any licensed Louisiana retail or mail-order pharmacy once a licensed provider writes you a valid prescription. This is the most legally straightforward route. The prescription drug can be ordered through specialty pharmacies and some mail-order services that ship to Louisiana.

Pathway 2: Compounded Bremelanotide From a 503A Pharmacy

A 503A state-licensed compounding pharmacy can prepare bremelanotide for an individual patient under a valid, patient-specific prescription. The FDA's current guidance on bulk drug substances governs whether a bulk active ingredient may legally be used. Bremelanotide is an FDA-approved drug, which means compounders may prepare it under 503A when a prescriber writes a patient-specific order and a commercially unavailable form is clinically justified (for example, a different concentration or delivery vehicle). The Louisiana Board of Pharmacy regulates in-state compounders and requires them to meet USP <795> and USP <797> standards for non-sterile and sterile preparations respectively.

Pathway 3: Telehealth Prescription in Louisiana

Louisiana permits telehealth prescribing of non-controlled substances when a valid patient-provider relationship exists. Bremelanotide is not a scheduled controlled substance. A licensed Louisiana provider, or an out-of-state provider licensed in Louisiana, can conduct a telehealth evaluation and issue a bremelanotide prescription that is filled at a licensed pharmacy. WomanRx operates exactly this model: a clinician reviews your medical history, discusses HSDD symptoms and contraindications, and routes your prescription to a licensed compounding or retail pharmacy.

What Is Not Legal

Buying PT-141 from a research-chemical website, a gym supplier, or an online vendor that does not require a prescription is not legal for human use in any U.S. State, including Louisiana. These sources sell bremelanotide labeled "not for human use" to circumvent FDA oversight. Purity, sterility, and accurate dosing cannot be verified. The FDA has issued warning letters to vendors selling peptides through this channel. If you are sourcing PT-141 this way, you are accepting unknown contamination risk.

What Is PT-141 (Bremelanotide) and Why Is It Relevant to Women?

Bremelanotide is a melanocortin receptor agonist that acts on the central nervous system, specifically on MC3R and MC4R receptors in the hypothalamus, to increase sexual desire. Unlike phosphodiesterase inhibitors (sildenafil, tadalafil), it does not work through vascular mechanisms. It works in the brain.

This mechanism is why it was developed for women. Male sexual dysfunction is primarily vascular. Female sexual dysfunction, particularly hypoactive sexual desire disorder (HSDD), is primarily central and neurochemical. HSDD affects an estimated 8 to 10 percent of women in the United States, making it the most common female sexual dysfunction diagnosis.

How the FDA Approval Happened

The FDA approved Vyleesi on June 21, 2019, based on two Phase 3 randomized controlled trials: RECONNECT Study 301 and Study 302. Across both trials, women using bremelanotide showed statistically significant improvement in sexual desire scores and reductions in distress related to low desire compared with placebo. Study 301 and 302 pooled data showed that approximately 25 percent of treated women reported a meaningful increase in satisfying sexual events per month versus 17 percent on placebo.

The approval is specifically for premenopausal women with acquired, generalized HSDD. "Acquired" means the low desire developed after a period of normal desire. "Generalized" means it occurs regardless of partner or situation.

The Two FDA-Approved Options for Female HSDD

Bremelanotide (Vyleesi) is one of only two FDA-approved pharmacological treatments for HSDD in women. The other is flibanserin (Addyi), a daily oral medication. The Menopause Society's 2022 position statement notes that both agents have modest but statistically significant effects and that patient preference for on-demand versus daily dosing is a clinically meaningful distinction. Bremelanotide's on-demand dosing is often preferred by women who want situational rather than continuous treatment.

Who This Is Right For (and Who Should Avoid It): A Life-Stage Guide

Premenopausal Women (Reproductive Years)

This is the FDA-approved population. If you are a woman with a menstrual cycle and you have noticed a drop in sexual desire that causes you personal distress, you are the intended candidate. The diagnosis of HSDD requires that the low desire causes meaningful distress to you, not just a difference from a partner's desire level.

You do not need to be in a relationship to be diagnosed. Solo desire, the presence of sexual thoughts and fantasies, is part of the clinical picture.

Perimenopausal Women

Perimenopause, the transition phase typically spanning 2 to 8 years before your final menstrual period, brings declining estrogen and progesterone levels that frequently reduce sexual desire. Bremelanotide was not specifically studied in perimenopausal women as a separate cohort. Clinicians may use it off-label for this group when the clinical picture fits HSDD. Your provider should document the off-label rationale.

Postmenopausal Women

The FDA approval does not extend to postmenopausal women. Data in this group are limited. A small open-label trial suggested potential benefit, but no Phase 3 data exist for postmenopausal women. If you are postmenopausal and experiencing low desire, your provider should first address genitourinary syndrome of menopause (GSM) with local estrogen or ospemifene, and consider whether systemic hormone therapy is appropriate, before discussing bremelanotide off-label.

Women With PCOS

PCOS is associated with androgen excess and, paradoxically, also with reduced sexual satisfaction and HSDD in some women, particularly those experiencing significant psychological distress related to the condition. A 2020 review in Fertility and Sterility noted the high prevalence of sexual dysfunction in PCOS. Bremelanotide has not been specifically studied in PCOS populations.

Women With Cardiovascular Disease

Bremelanotide causes a transient increase in blood pressure averaging 6 mmHg systolic and 3 mmHg diastolic, peaking at approximately 30 to 60 minutes post-injection and resolving within 12 hours. The FDA label contraindicates use in women with known cardiovascular disease. This is a firm contraindication, not a caution.

Women Who Should Not Use Bremelanotide

• Pregnant women (see pregnancy section below)
• Women with cardiovascular disease, including uncontrolled hypertension
• Women using naltrexone (antagonist interaction at opioid receptors reduces bremelanotide clearance)
• Women with a history of severe nausea or hypersensitivity to the drug

Pregnancy, Lactation, and Contraception: What You Must Know

Bremelanotide is contraindicated in pregnancy. This is not a theoretical concern.

Animal and Human Pregnancy Data

Animal reproductive studies showed fetal harm at doses that produce systemic exposures similar to those in humans. The FDA label assigns bremelanotide to a category that advises against use in pregnancy, citing the animal data and the absence of adequate human pregnancy studies. No well-controlled human pregnancy data exist. Based on the mechanism of action (melanocortin receptor agonism affecting hypothalamic signaling), fetal exposure is a genuine concern.

Contraception Requirement

Because bremelanotide is used in premenopausal women who may be of reproductive age, your prescriber should confirm that you are using reliable contraception before initiating treatment or that pregnancy is otherwise not possible. This is not optional clinical practice. It is part of responsible prescribing for this drug.

If you are trying to conceive, bremelanotide is not appropriate for you at this time.

Lactation

No human data exist on the transfer of bremelanotide into breast milk, the effects on the breastfed infant, or the effects on milk production. Animal lactation data are also limited. The FDA label recommends against use during breastfeeding. If you are postpartum and breastfeeding and experiencing low desire (which is extremely common in the postpartum period due to suppressed estrogen and elevated prolactin), discuss non-pharmacological approaches and the timing of potential treatment after lactation ends.

Postpartum Low Desire

Postpartum HSDD is common and, in most cases, resolves with the return of ovarian function after weaning. Before initiating any pharmacological treatment, a thorough postpartum assessment should rule out postpartum depression, relationship distress, sleep deprivation, and prolactin-related suppression of desire as contributing factors.

How the Federal and Louisiana State Regulatory Framework Works Together

Understanding the legal framework helps you ask better questions of any provider or pharmacy.

Federal Level: FDA Approval and Scheduling

Bremelanotide is an FDA-approved prescription drug. It is not a scheduled controlled substance under the DEA's Controlled Substances Act schedules. This means it does not require DEA Schedule II-V prescribing protocols, triplicate prescriptions, or special pharmacy registration to dispense. Any licensed prescriber with a DEA number can prescribe it; they do not need a special DEA registration for controlled substances to do so.

503A vs 503B Compounding

Two federal compounding pathways exist.

503A pharmacies compound for individual patients under a valid prescription. They are regulated primarily by state boards of pharmacy, with FDA oversight of bulk ingredient safety. Louisiana-licensed 503A compounders can legally compound bremelanotide for individual patient prescriptions. These pharmacies cannot compound large batches without individual prescriptions.

503B outsourcing facilities compound larger batches and may or may not require individual prescriptions. They are federally registered with the FDA and subject to current good manufacturing practice (cGMP) standards. Bremelanotide from a 503B facility is legal when dispensed to practitioners for office use or with a prescription.

The FDA's bulk drug substance lists define which ingredients may be used. Because bremelanotide is an already-approved drug, it occupies a different regulatory position than peptides like BPC-157 or TB-500 that have never received FDA approval and sit on a more contested legal footing.

Louisiana Board of Pharmacy Rules

The Louisiana Board of Pharmacy requires that compounding pharmacies comply with USP standards and that all compounded preparations are dispensed pursuant to a valid patient-specific prescription. Louisiana does not have a separate state law that bans or restricts bremelanotide beyond these standard pharmacy board requirements. There is no Louisiana statute that schedules or prohibits bremelanotide.

The Louisiana Medical Practice Act governs what licensed physicians, NPs, and PAs may prescribe. Prescribing bremelanotide off-label (for example, in postmenopausal women or for indications other than HSDD) is legally permitted under medical practice acts as long as the provider documents clinical rationale and acts within their standard of care.

The WomanRx Legal-Access Framework for PT-141 in Louisiana

| Access Path | Legal? | Requires Rx? | Notes | |---|---|---|---| | Brand Vyleesi from retail pharmacy | Yes | Yes | Highest regulatory certainty | | Compounded bremelanotide from 503A Louisiana pharmacy | Yes | Yes | Must be patient-specific | | Compounded bremelanotide from 503B outsourcing facility | Yes | Generally yes for outpatient use | cGMP standards apply | | Telehealth Rx + licensed pharmacy | Yes | Yes | Valid patient-provider relationship required | | Research-chemical website, no Rx | No | No Rx required by seller | Illegal for human use; avoid |

Side Effects Women Report Most Often

The pooled RECONNECT trial data identified these adverse effects as most common in women:

• Nausea: 40 percent of bremelanotide users vs 1 percent of placebo users. This is the most common reason women discontinue.
• Flushing: 20 percent
• Injection-site bruising or discomfort: 13 percent
• Headache: 11 percent
• Transient blood pressure elevation: documented in nearly all users, typically self-resolving within 12 hours

The nausea rate is significant. Many prescribers recommend taking an anti-nausea medication such as ondansetron 30 minutes before the bremelanotide injection for the first several uses. Discuss this with your provider before your first dose.

Hyperpigmentation of the face, gums, or breasts has been reported with repeated use, particularly in women with darker skin tones. This is related to melanocortin receptor activation. It is typically reversible after stopping the drug but may take weeks to resolve.

How to Get a Legal PT-141 Prescription in Louisiana: Step by Step

1. Find a licensed Louisiana provider (physician, NP, or PA) with experience in female sexual health. Telehealth platforms including WomanRx can connect you with a qualified clinician without requiring an in-person office visit for non-controlled substances.

2. Complete a thorough intake. Your provider should screen for cardiovascular disease, current medications (especially naltrexone or any opioid), pregnancy status, and the clinical criteria for HSDD (low desire causing personal distress, not better explained by another condition or medication).

3. Receive your prescription. The provider sends a prescription to a licensed pharmacy of your choice, whether a retail pharmacy dispensing Vyleesi or a licensed compounding pharmacy preparing a specific formulation.

4. Confirm your pharmacy's license. For compounders, verify Louisiana Board of Pharmacy licensure. For out-of-state mail-order compounders shipping to Louisiana, confirm they hold a Louisiana non-resident pharmacy permit.

5. Obtain your medication and review the injection instructions. Bremelanotide is a subcutaneous injection. Your provider or pharmacist should review proper technique, injection sites (abdomen or thigh), and storage requirements (typically refrigerated).

What the Evidence Actually Shows: Honest Numbers

The FDA approval was based on statistically significant but modest effect sizes. Across the RECONNECT trials, the average increase in satisfying sexual events per month was approximately 0.5 events in the bremelanotide group vs 0.2 in placebo. The Female Sexual Function Index desire domain score improved by approximately 0.3 points more than placebo on a 6-point scale.

These numbers are real and they are not large. Some women experience dramatic improvement; others notice little change. The drug works best when HSDD is the primary diagnosis and is not secondary to relationship distress, depression, pain disorders, or medication side effects.

Women have been historically underrepresented in sexual-health pharmacology trials, and the RECONNECT trials were a meaningful exception because they enrolled exclusively women. The data are directly applicable to female patients in a way that most cardiovascular or metabolic drug trials are not. The trial population was predominantly white and premenopausal, and extrapolation to women of other racial and ethnic backgrounds or to perimenopausal and postmenopausal women should be done with appropriate caution.

A 2023 review in the Journal of Sexual Medicine noted that real-world discontinuation rates for bremelanotide are higher than trial dropout rates, primarily because of nausea. Proactive nausea management before the first dose substantially improves persistence.

Questions to Ask Your Provider Before Starting

• Is my low desire pattern consistent with acquired generalized HSDD or is there a secondary cause we should address first?
• Do I need any cardiovascular screening before starting?
• What is your approach to managing nausea with the first dose?
• Should I use the brand Vyleesi or a compounded formulation, and what is the clinical rationale for that choice?
• How many uses should I try before deciding whether it is working?
• What should I do if I notice skin darkening?